Australia’s Groundbreaking Stem Cell Sciences Closed By New U.S. Owner
This article was originally published in PharmAsia News
Executive Summary
Stem Cell Sciences, Australia's first stem-cell biotech, is going out of business, the result of a decision by its new U.S. owner. StemCells of California acquired the intellectual property of SCS for handling embryonic stem cells and other technology along with patents on 20 sets of products. The closing of SCS leaves Australia with only Mesoblast, since Bresagen ended its stem-cell work and Embryonic Stemcells relocated to Singapore. The California company bought SCS in March for $4 million. (Click here for more
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.